A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

NCT07105488 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

225

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis (AD)

Interventions

BIOLOGICAL: BFB759
DRUG: Placebo

Sponsor

Bluefin Biomedicine, Inc.